中国慢性乙型肝炎(简称“慢乙肝”)患者的“治愈”故事,正在萌芽。 8月31日—9月5日,在新加坡召开的亚洲肝病学峰会(AHS)暨HBV(乙型肝炎病毒)治愈科学会议上,反义寡核苷酸(ASO)药物Bepirovirsen全球Ⅲ期研究(B-Well研究)的中国人群数据完成了全球首秀:中国慢乙肝患者功能性治愈率最高可达61%,疗效与安全性趋势与全球数据一致。 在会议召开前一周,Bepirovirsen...
Source Link中国慢性乙型肝炎(简称“慢乙肝”)患者的“治愈”故事,正在萌芽。 8月31日—9月5日,在新加坡召开的亚洲肝病学峰会(AHS)暨HBV(乙型肝炎病毒)治愈科学会议上,反义寡核苷酸(ASO)药物Bepirovirsen全球Ⅲ期研究(B-Well研究)的中国人群数据完成了全球首秀:中国慢乙肝患者功能性治愈率最高可达61%,疗效与安全性趋势与全球数据一致。 在会议召开前一周,Bepirovirsen...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.